Добірка наукової літератури з теми "Insulin-like growth factor-binding proteins"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Insulin-like growth factor-binding proteins".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

За допомогою хмари тегів ви можете побачити ще більше пов’язаних тем досліджень, а відповідні кнопки після кожного розділу сторінки дозволяють переглянути розширені списки книг, статей тощо на обрану тему.

Пов'язані теми наукових робіт:

Статті в журналах з теми "Insulin-like growth factor-binding proteins":

1
Bach, Leon A. "Insulin-like growth factor binding proteins 4-6." Best Practice & Research Clinical Endocrinology & Metabolism 29, no. 5 (October 2015): 713–22. http://dx.doi.org/10.1016/j.beem.2015.06.002.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Baxter, Robert C. "Insulin-like growth factor binding proteins as glucoregulators." Metabolism 44 (October 1995): 12–17. http://dx.doi.org/10.1016/0026-0495(95)90215-5.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Coverley, J. A., and R. C. Baxter. "Phosphorylation of insulin-like growth factor binding proteins." Molecular and Cellular Endocrinology 128, no. 1-2 (April 1997): 1–5. http://dx.doi.org/10.1016/s0303-7207(97)04032-x.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4
Collet, Chris, and Judith Candy. "How many insulin-like growth factor binding proteins?" Molecular and Cellular Endocrinology 139, no. 1-2 (April 1998): 1–6. http://dx.doi.org/10.1016/s0303-7207(98)00078-1.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5
Leroith, Derek. "Insulin-like growth factor receptors and binding proteins." Baillière's Clinical Endocrinology and Metabolism 10, no. 1 (January 1996): 49–73. http://dx.doi.org/10.1016/s0950-351x(96)80298-9.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
Ferry Jr., Robert J., Ruben W. Cerri, and Pinchas Cohen. "Insulin-Like Growth Factor Binding Proteins: New Proteins, New Functions." Hormone Research in Paediatrics 51, no. 2 (1999): 53–67. http://dx.doi.org/10.1159/000023315.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Feld, Stella M., and Raimund Hirschberg. "Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome." Pediatric Nephrology 10, no. 3 (June 1996): 355–58. http://dx.doi.org/10.1007/bf00866783.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8
Feld, Stella M., and Raimund Hirschberg. "Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome." Pediatric Nephrology 10, no. 3 (May 1996): 355–58. http://dx.doi.org/10.1007/s004670050124.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
Rosen, Clifford J. "Serum Insulin-like Growth Factors and Insulin-like Growth Factor-binding Proteins: Clinical Implications." Clinical Chemistry 45, no. 8 (August 1999): 1384–90. http://dx.doi.org/10.1093/clinchem/45.8.1384.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract The last decade has been characterized by a major investigative thrust into the physiology of two unique but ubiquitous peptides, insulin-like growth factor (IGF)-I and IGF-II. The regulatory systems that control the tissue bioactivity of the IGFs have been delineated, and subcellular signaling mechanisms have been clarified. Clearly, both tissue and circulating growth factor concentrations are important in defining the relationship between IGF-I and cell activity. Bone, liver, and circulatory IGF-I have received the most attention by investigators, in part because of the ease of measurement and the interaction with disease states such as osteoporosis. More recently, attention has focused on the role IGF-I plays in neoplastic transformation and growth. Two large prospective observational studies have demonstrated greater risk for prostate and breast cancer associated with high circulating concentrations of IGF-I. Animal models and in vitro studies confirm that there is a close, albeit complex, interaction between IGF-I signaling and bone turnover. This report will focus on: (a) IGF physiology, including IGF ligands, binding proteins, and proteases; (b) the relationship between IGF-I and bone mass in respect to risk for osteoporosis; (c) the heritable regulation of the IGF-I phenotype; and (d) the association between serum IGF-I and cancer risk. The IGFs remain a major area for basic and clinical investigations; future studies may define both diagnostic and therapeutic roles for these peptides or their related proteins in several disease states.
10
Cara, José F. "Insulin-Like Growth Factors, Insulin-Like Growth Factor Binding Proteins and Ovarian Androgen Production." Hormone Research 42, no. 1-2 (1994): 49–54. http://dx.doi.org/10.1159/000184145.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Дисертації з теми "Insulin-like growth factor-binding proteins":

1
Hopkins, Nicholas John. "Insulin-like growth factor-I and its binding proteins." Electronic Thesis or Dissertation, University of Reading, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.240702.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Clark, Sarah Jane. "The growth hormone, insulin-like growth factor, insulin-like growth factor binding proteins and insulin axis in acute liver failure." Electronic Thesis or Dissertation, King's College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.397943.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Mireuta, Matei. "Aspects of insulin-like growth factor binding proteins in cancer." Electronic Thesis or Dissertation, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=114128.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The insulin-like growth factor (IGF) system is composed of two ligands (IGF-1 and IGF-2), two receptors (IGF-1R and IGF-2R) and six binding proteins (IGFBP-1 to -6). IGFs act as endocrine, paracrine and autocrine growth factors and stimulate cell growth, proliferation and metabolism. There is extensive evidence, both from in vitro and in vivo models as well as population studies, that IGF physiology is relevant to neoplasia. IGF-1R is the physiologic receptor for both ligands and its activation elicits a plethora of changes at the cellular level, such as activation of PI3K/AKT/mTOR and Ras/Raf/MAP kinase pathways. Given its role in the maintenance and promotion of neoplasia, the IGF system represents a potential target in the context of cancer therapy.Classically, IGFBPs have been described as carrier proteins for IGFs in the blood and other fluids. They can regulate IGF bioavailability both positively through increases in ligand half-life as well as negatively through competition with the IGF-1R for ligand binding. In addition to their classical roles, there is evidence suggesting that IGFBPs can act independently of IGFs by poorly characterized mechanisms. Additionally, epidemiologic studies have correlated overexpression of certain IGFBPs, in particular IGFBP-2, with poor prognosis in various cancers.Although the role of IGFBPs has been extensively studied in the context of both normal and malignant growth, this thesis describes several new aspects of IGFBPs in neoplasia. In the second chapter, we study the effect of the PI3K/AKT/mTOR cascade on IGFBP-2 gene expression in a breast cancer cell line in vitro. We demonstrate that activation of this pathway essentially leads to an Sp1-dependent increase in IGFBP-2 gene transcription. We further show that Sp-1 is phosphorylated upon PI3K/AKT/mTOR pathway activation and accumulates in the nucleus. In the third chapter, we study the effects of 2-deoxyglucose (2-DG) on IGF-1:IGFBP-3 complex formation. A recent publication suggested that 2-DG unexpectedly disrupted IGF-1:IGFBP-3 binding leading to increases in IGF-1R and AKT signaling in various cell lines. We show by three different techniques that neither 2-DG nor glucose affect IGF-1:IGFBP-3 complex formation. We additionally show that the 2-DG effects observed are not consistent between cell lines and likely the result of changes in intracellular signaling. In the fourth chapter, we study the effects of a novel therapeutic antibody (BI836845) with high affinity for both IGF-1 and IGF-2. In mouse serum samples ex vivo, we show that the addition of BI836845 leads to a shift of IGF-1 from the IGFBPs to the antibody. In vivo, we demonstrate that BI836845 binds the vast majority of IGF-1. Finally, we demonstrate that BI836845 induces a decrease in IGFBP-3 and an increase in growth hormone levels in C57 BL/6 mice.
L'ensemble du système de facteurs de croissance insulinomimétique (IGF) est composé de deux ligands (IGF-1 et IGF-2), de deux récepteurs (IGF- 1R et IGF-2R) et de six protéines de liaison (IGFBP-1 à 6). Les IGFs sont des hormones endocrines, paracrines et autocrines qui stimulent la croissance cellulaire, la prolifération et le métabolisme. Il existe un grand nombre d'études utilisant des approches épidémiologiques ou des modèles in vivo et in vitro qui démontrent l'importance des IGFs dans le contexte du cancer. Le IGF-1R est le récepteur physiologique des deux ligands et son activation mène à d'importants changements cellulaires tels que l'activation des voies de signalisation PI3K/AKT/mTOR et Ras/Raf/MAPK. Étant donné son rôle dans la promotion et dans la progression du cancer, le système des IGFs représente une cible potentielle pour le traitement du cancer. De façon classique, les protéines de liaison IGFBP ont été décrites comme de simples porteurs d'IGFs dans le sang et autres fluides. Les IGFBPs peuvent modifier la biodisponibilité des IGFs de façon positive en augmentant leur demi-vie ou de façon négative due à leur compétition avec le IGF-1R pour la liaison. En plus de leur rôle classique, il est de plus en plus évident que ces protéines peuvent agir de manière indépendante, mais les mécanismes impliqués restent flous. Également, il existe des études épidémiologiques qui ont corrélé la surexpression de IGFBPs, en particulier IGFBP-2, avec un pronostic défavorable dans plusieurs formes de cancer. Bien que le rôle des IGFBPs ait été largement étudié dans le contexte de la croissance normale et en néoplasie, la présente thèse révèle quelques nouveaux aspects de la physiologie des IGFBPs dans le contexte du cancer. En première partie, nous étudions l'effet de la voie de signalisation PI3K/AKT/mTOR sur l'expression du gène IGFBP-2 dans une lignée cellulaire de cancer du sein. Nous démontrons que l'activation de cette voie mène essentiellement à une augmentation de la transcription de ce gène de manière dépendante au facteur de transcription Sp-1. De plus, nous établissons que Sp-1 est phosphorylé par l'activation de la voie PI3K/AKT/mTOR et s'accumule dans le noyau. En deuxième partie, nous étudions les effets de la molécule 2-deoxyglucose (2-DG) sur la liaison entre IGF-1 et IGFBP-3. Un récent article avait suggéré un effet inhibitoire de cette molécule sur la formation de complexes IGF -1 :IGFBP-3. Nous démontrons par trois méthodes différentes que 2-DG ou la molécule apparentée glucose n'ont aucun effet sur la liaison entre IGF-1 et IGFBP-3. De plus, nous démontrons que les effets cellulaires de 2-DG sur l'activation de la voie PI3K/AKT/mTOR observées par les auteurs de l'article en question ne sont pas universels et sont probablement le résultat de signaux intracellulaires. Finalement, en dernière partie, nous étudions les effets d'un nouvel anticorps thérapeutique nommé BI836845 qui possède une grande affinité pour IGF-1 et IGF-2. Dans des échantillons de sérum de souris ex vivo, nous démontrons que l'ajout de BI836845 déplace IGF-1 des complexes naturels contenant les IGFBPs vers des complexes contenant l'anticorps. In vivo, nous démontrons que BI836845 lie la grande majorité d'IGF-1. Nous démontrons aussi que l'anticorps mène à une baisse de la concentration de IGFBP-3 et à une hausse de la concentration de l'hormone de croissance chez des souris C57 BL/6.
4
Nickerson, Tara. "A role for insulin-like growth factor binding proteins in apoptosis /." Electronic Thesis or Dissertation, McGill University, 1999. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=35923.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Insulin-like growth factors have well characterized mitogenic and antiapoptotic effects in a number of normal and transformed cell types that are mediated through binding to the IGF-I receptor. IGF activity is modulated by at least six insulin-like growth factor binding proteins (IGFBPs) that bind IGFs with high affinity. Recently, it has been proposed that IGFBPs may play an important role in regulating apoptosis. This thesis provides evidence that IGFBPs induce apoptosis in vitro, and are associated with involution of ventral prostate and with regression of androgen-dependent and estrogen-dependent tumors in vivo. We show here that IGFBP-3 induces apoptosis in MCF7 breast cancer cells, and that apoptosis induced by the antiestrogen ICI 182,780 is mediated in part by increased IGFBP-3 accumulation. In the normal rat prostate, increased expression of genes encoding IGFBPs 2,3,4 and 5 is observed during apoptosis induced by castration, the antiandrogen bicalutamide, or the vitamin D3 analogue EB1089. A dramatic increase in IGFBP-5 gene expression is observed during castration-induced apoptosis in androgen-dependent Shionogi tumors. Inhibition of apoptosis in Shionogi tumors with calcium channel blockers attenuates castration-induced IGFBP-5 expression. These results indicate that IGFBP-5 gene expression is related to apoptosis, rather than being strictly under hormonal regulation. Increased expression of IGFBPs 2,3,4 and 5 is observed in regression of DMBA-induced rat mammary tumours induced by estrogen-ablation. Rapid induction of IGFBPs can limit access of IGFs to the IGF-I receptor and may therefore initiate induction of apoptosis. Taken together, these results demonstrate that IGFBPs play a role in apoptosis and suggest that strategies which target IGF pathways may augment the actions of hormone-targeting therapies for breast and prostate cancer prevention and treatment by enhancing apoptosis in tumors.
5
Nickerson, Tara. "A role for insulin-like growth factor binding proteins in apoptosis." Electronic thesis or dissertation, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0022/NQ50229.pdf.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
de, los Rios Patricia. "Insulin-like growth factor binding proteins (IGFBPs) in ovine fetal growth plate chondrocytes." Electronic thesis or dissertation, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0011/MQ28557.pdf.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Burk, John Robert. "Insulin-like Growth Factor Binding Proteins in the Plasma of Growing Horses." Thesis, Virginia Tech, 2003. http://hdl.handle.net/10919/31712.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Insulin-like growth factor binding proteins (IGFBP) are modulators of insulin-like growth factor I (IGF-I), which functions as a regulator of cartilage and bone development. Rapid growth and high starch diets have been associated with increased circulating concentrations of IGF-I, which lead to developmental orthopedic disorders in foals. The objective of this study was to assess the effects of age, diet, growth and season on plasma IGFBP and IGF-I concentrations from birth to 16 mo of age in Thoroughbred foals. Twenty-two mares maintained on mixed grass/legume pasture were randomly divided into two dietary groups and fed either a high starch and sugar supplement (SS) or a starch-restricted fiber and fat supplement (FF) for 3 mo prior to and after foaling. Monthly blood samples were obtained from SS and FF foals up to 16 mo of age and analyzed for IGF-I using an RIA and IGFBP using western ligand blot analysis. Auxilogical measurements of foals were also obtained each month. The effect of diet, month, and diet*month interactions upon the subject horse (diet) were analyzed using a mixed model with repeated measures, and correlations of normally distributed data were calculated using Pearsonâ s correlation. Six IGFBP bands of molecular weights 109, 39, 36, 35, 34, and 33 kDa were identified in foal plasma. Doublet bands were recognized at 109, 39, and 35 kDa, however they were not all believed to be singular pure IGFBP. A band with a molecular weight of 213 kDa was observed and presumed to be a ternary complex of IGFBP-3, IGF-I, and an acid labile subunit. The IGFBP 109 kDa has been previously recognized as a band unique to the equine, it was not a singular pure IGFBP because of its high molecular weight. No effect of diet on plasma IGFBP was found in individual sampling of yearlings, but an effect of month was noted when testing May - August 2001 against May - August 2002 in pooled plasma samples with concentrations of the IGFBP 39 kDa increasing (P < 0.0003). In contrast, concentrations of the IGFBPâ s 33, 34 and 36 kDa decreased (P < 0.003, P < 0.0002, and P < 0.0003 respectively). Environmental effects were noted upon IGFBPâ s 33, 36, 39, and 109 kDa (P < 0.003, P < 0.001, P < 0.04, and P < 0.01) with a temperature*daylength interaction. Correlations existed between ADG and IGFBP 33 (r = 0.64; P < 0.0001), 34 (r = 0.40; P < 0.0001), 35 (r = 0.33; P < 0.0006), 36 (r = 0.47; P < 0.0001), and 39 kDa (r = - 0.18, P < 0.02). A correlation was also found between IGF-I and ADG (r = 0.11; P < 0.04), confirming the previously reported relationship of IGF-I in growth rate of foals. These results underline the importance of characterizing the activity of IGFBPâ s in relation to growth, age and season when interpreting changes of the somatotropic axis. Further, the increase in certain IGFBPâ s and simultaneous decrease in others stress the need for further research on the tissue specific modulating effects that IGFBPâ s have on IGF-I.
Master of Science
8
Wang, Jing. "Novel insulin-like growth factor-binding protein proteases: detection and characterization /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-942-4/.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
Whellams, Emma Jane. "The role and regulation of insulin like growth factor binding proteins in arthritis." Electronic Thesis or Dissertation, University of Bristol, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324333.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10
Carr, Jillian M. "Insulin-like growth factor binding proteins (IGFBPs) in growth and development of the ovine fetus." Adelaide Thesis (Ph.D.) -- University of Adelaide, Department of Biochemistry, 1994. http://hdl.handle.net/2440/21607.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Insulin-like growth factor-binding proteins":

1
White, Darren Andrew. An analytical study of insulin-like growth factor binding proteins in human serum. Birmingham: University of Birmingham, 1995.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Colloque, médecine et recherche (8th :. 2008 Paris France). IGFs: Local repair and survival factors throughout life span. Heidelberg: Springer, 2010.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Alcuin, Symposium (2000 Aachen Germany). Insulin & related proteins: Structure to function and pharmacology. Dordrecht: Kluwer Academic Publishers, 2002.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4
Westwood, Melissa. Biochemical characterisation of insulin-like growth factor binding protein-1. Manchester: University of Manchester, 1994.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5
LeRoith, Derek. Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics. Boston, MA: Springer Science+Business Media, LLC, 2012.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
Lawlor, Margaret Ann. The role of the insulin-like growth factor-II/mannose-6-phosphate receptor in embryonic development. Dublin: University College Dublin, 1998.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Mapoko, Ilondo Mbelenge. Cellular receptors for human growth hormone: Quantitative aspects and clinical applications. Leuven: Leuven University Press, 1988.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8
Sekyi-Otu, Ato. Insulin-like growth factor responsiveness in sarcomas. Ottawa: National Library of Canada, 1993.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
International, Symposium on Insulin-Like Growth Factors (4th 1997 Tokyo Japan). Molecular mechanisms to regulate the activities of insulin-like growth factors: Proceedings of the 4th International Symposium on Insulin-like Growth Factors, at Tokyo International Forum, Tokyo, Japan, 21-24 October 1997. Amsterdam: Elsevier, 1998.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10
Michell, Nicholas Paul. An exploration of insulin-like growth factors and their binding proteins in colonic cancer. Birmingham: University of Birmingham, 1998.
Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Insulin-like growth factor-binding proteins":

1
Holly, Jeff M. P., and Janet K. Fernihough. "The Insulin-Like Growth Factor (IGF) Binding Proteins (IGFBPS)." In Growth Hormone, 77–96. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5163-8_5.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Baxter, R. C. "Insulin-like Growth Factor Binding Proteins: Biochemical Characterization." In Growth Hormone and Somatomedins during Lifespan, 100–108. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78217-6_9.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Wilczak, Nadine, and Jacques de Keyser. "Insulin-Like Growth Factor System in Amyotrophic Lateral Sclerosis." In IGF-I and IGF Binding Proteins, 160–69. Basel: KARGER, 2005. http://dx.doi.org/10.1159/000085764.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4
Clemmons, D. R. "Role of Insulin-like Growth Factor Binding Proteins in Modulating Insulin-like Growth Factor Action." In Growth Hormone and Somatomedins during Lifespan, 109–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78217-6_10.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5
Ocrant, Ian. "Insulin-Like Growth Factor Binding Proteins in the Nervous System." In Advances in Experimental Medicine and Biology, 471–82. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5949-4_42.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
Minniti, Giuseppe, and Youngman Oh. "Insulin-Like Growth Factor Binding Proteins in Endocrine-Related Neoplasia." In Endocrine Oncology, 215–35. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-223-4_11.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Bidlingmaier, M. "Insulin-like growth factor binding protein-3." In Springer Reference Medizin, 1257–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_1585.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8
Seth, John. "Insulin-Like Growth Factor Binding Protein-1." In The Immunoassay Kit Directory, 206. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_31.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
Seth, John. "Insulin-Like Growth Factor Binding Protein-3." In The Immunoassay Kit Directory, 207–9. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_32.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10
Bidlingmaier, M. "Insulin-like growth factor binding protein-3." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_1585-1.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Insulin-like growth factor-binding proteins":

1
Park, Jae-Hyun, Morten Grønbech Rasch, Jing Qiu, Ida Katrine Lund, Zena Werb, and Mikala Egeblad. "Abstract 2465: Matrix metalloproteinase 9 promotes breast cancer through regulation of insulin-like growth factor-binding proteins." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2465.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Rice, Megan S., Rulla M. Tamimi, James L. Connolly, Laura C. Collins, Dejun Shen, Michael N. Pollak, Bernard Rosner, Susan E. Hankinson, and Shelley S. Tworoger. "Abstract A68: Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and lobule type in the Nurses' Health Study II." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Oct 22-25, 2011; Boston, MA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1940-6207.prev-11-a68.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Bruns, Alexander-Francisco, Jessica Smith, Pooja Shah, Nadira Yuldasheva, Mark T. Kearney, and Stephen Wheatcroft. "145 Insulin-like growth factor binding protein 2 (igfbp2) positively regulates angiogenesis." In British Cardiovascular Society Annual Conference ‘High Performing Teams’, 4–6 June 2018, Manchester, UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcs.141.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4
Dar, Altaf A. "Abstract 5004: Functional modulation of insulin-like growth factor binding protein-3 in melanoma." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5004.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5
Silvers, Amy L., Lin Lin, David G. Beer, and Andrew C. Chang. "Abstract 830: Insulin-like growth factor binding protein-2 and chemosensitivity in esophageal adenocarcinoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-830.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
Contois, Liangru W., Jennifer M. Caron, Eric Tweedie, Leonard Liebes, Robert Friesel, Calvin Vary, and Peter C. Brooks. "Abstract 3485: Insulin-like growth factor binding protein-4 (IGFBP-4) differentially inhibits growth factor induced angiogenesis in vivo." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3485.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Ibrahim, YH, J. Hartel, K. La Parra, and D. Yee. "Insulin-like growth factor binding protein-1 (IGFBP-1) targets both the insulin-like growth factor (IGF) and integrin pathways for the inhibition of breast cancer cell motility." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-402.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8
Ahasic, Amy M., Rihong Zhai, Li Su, Konstantinos Aronis, Christos S. Mantzoros, B. T. Thompson, and David C. Christiani. "IGFBP3 Polymorphism Is Associated With Plasma Insulin-Like Growth Factor (IGF)-1 And Insulin-Like Growth Factor Binding Protein (IGFBP-3) In An Intensive Care Unit (ICU) Cohort." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3545.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
Yerushalmi, R., B. Gilks, T. Nielsen, S. Leang, M. Cheang, R. Woods, K. Gelmon, and H. Kennecke. "Insulin like growth factor in breast cancer subtypes." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3048.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10
Aditya Prayudi, Pande Kadek, I. Nyoman Gede Budiana, and Ketut Suwiyoga. "54 Diagnostic accuracy of serum insulin-like growth factor binding protein 2 for ovarian cancer." In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.97.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Insulin-like growth factor-binding proteins":

1
Harbeson, Caroline E., and Steven A. Rosenzweig. The Role of Insulin-Like Growth Factor (IGF) Binding Proteins (IGFBPs) in IGF-Mediated Tumorigenicity. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada420331.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2
Gross, Jennifer M. Insulin-Like Growth Factor Binding Protein-1 Interacts with Integrins to Inhibit Insulin-Like Growth Factor-Induced Breast Cancer Growth and Migration. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada420347.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3
Harbeson, Caroline E., and Steven A. Rosenzweig. The Role of the Insulin-Like Growth Factor (IGF) Binding Proteins (IGFBPs) in IGF-Mediated Tumorigenicity. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada409808.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4
Schoen, Timothy J. Expression and Characterization of Insulin-Like Growth Factor Binding Proteins (IGFBPs) and IGFBP-2 mRNA in the Developing Chicken Eye. Fort Belvoir, VA: Defense Technical Information Center, March 1995. http://dx.doi.org/10.21236/ad1011459.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5
Rosenfeld, Ron G. A Novel Member of the Insulin-Like Growth Factor Binding Protein Superfamily in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2001. http://dx.doi.org/10.21236/ada393860.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6
Rosenfeld, Ron G. A Novel Member of the Insulin-Like Growth Factor Binding Protein Superfamily in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2004. http://dx.doi.org/10.21236/ada438221.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7
Rosenfeld, Ron G. A Novel Member of the Insulin-Like Growth Factor Binding Protein Superfamily in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2002. http://dx.doi.org/10.21236/ada406049.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8
Cleveland, Rebecca J., Marilie D. Gammon, and Ralph S. Baric. Insulin-Like Growth Factor I Polymorphisms in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada412654.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9
Erickson, Keesha E., Oleksii S. Rukhlenko, Md Shahinuzzaman, Kalina P. Slavkova, Yen Ting Lin, Edward C. Stites, Marian Anghel, et al. Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor. Office of Scientific and Technical Information (OSTI), September 2018. http://dx.doi.org/10.2172/1473773.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10
Dodd, Janice G. In Vivo Activity of Insulin-Like Growth Factor Binding Protein-3 in Prevention of Prostate Cancer Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2008. http://dx.doi.org/10.21236/ada519976.
Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

До бібліографії

Будь ласка, вимкніть ваш блокувальник реклами

Adblock logo Adblock logo Adblock logo

"Grafiati" – це незалежний сервіс, що забезпечує унікальну якість оформлення бібліографічних посилань. Ви можете користуватися нашим сайтом безоплатно, дозволивши показ реклами, або оформити передплату.

Передплатити